4871 T3D4816 Salicylic acid A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics. 69-72-7 338 C7H6O3 138.12 White powder. 158°C 211°C at 2.00E+01 mm Hg 2240 mg/L (at 25°C) Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis. Oral rat LD50: 891 mg/kg. Inhalation rat LC50: > 900 mg/m3/1hr. Irritation: skin rabbit: 500 mg/24H mild. Eye rabbit: 100 mg severe. No indication of carcinogenicity to humans (not listed by IARC). Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts. Investigated as a mutagen and reproductive effector. 2014-09-11T05:17:50Z 2026-05-14T16:53:20Z Salicyclic_acid C00805 16914 DB00936 SAL true OC(=O)C1=CC=CC=C1O C7H6O3 InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10) YGSDEFSMJLZEOE-UHFFFAOYSA-N 138.122 138.031694053 Exogenous Solid 2.26 HMDB01895 CHEMBL424 331 <p>Howard Jones, Robert W. Houser, &#8220;Process for preparing 4-(2,4-difluorophenyl)-salicyclic acid.&#8221; U.S. Patent US4225730, issued August, 1972.</p> CHEM003773 DTXSID7026368 NS00010274 2-hydroxybenzoic acid 57.53 35.2951 12.814587378025518 1 3 2 2.7897391795725692 -6.285929432184692 -1 1 1.96 -1.09 1.13e+01 g/l